Newbury Pharmaceuticals AB (OSTO:NEWBRY) Shareholder Yield % : 0.00% (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NEWBRY Newbury Pharmaceuticals AB OSTO:NEWBRY
41 GF Score
Price kr2.48
GF Value kr3.20
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Newbury Pharmaceuticals AB Shareholder Yield %?

Newbury Pharmaceuticals AB OSTO:NEWBRY -4.62% 41 Shareholder Yield % is 0.00% as of Feb. 2026. GuruFocus rates OSTO:NEWBRY with a GF Score™ of 41/100 and a GF Value™ of kr3.20 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 966 Drug Manufacturers companies, Newbury Pharmaceuticals AB ranks worse than 103519.57% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Newbury Pharmaceuticals AB's Shareholder Yield % was 0.00%.


Newbury Pharmaceuticals AB  (OSTO:NEWBRY) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Newbury Pharmaceuticals AB Shareholder Yield % Related Terms


Newbury Pharmaceuticals AB Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Newbury Pharmaceuticals AB's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newbury Pharmaceuticals AB Shareholder Yield % Chart

Newbury Pharmaceuticals AB Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Shareholder Yield %
0.00 -51.85 0.00 -22.69 -19.53

Newbury Pharmaceuticals AB Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -19.53 0.00 0.00

OSTO:NEWBRY vs ZTS, UTHR, VTRS: Shareholder Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Newbury Pharmaceuticals AB Shareholder Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Newbury Pharmaceuticals AB's Shareholder Yield % falls into.


OSTO:NEWBRY
41GF Score
Newbury Pharmaceuticals AB OSTO:NEWBRY
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newbury Pharmaceuticals AB Shareholder Yield % Calculation

Newbury Pharmaceuticals AB's Shareholder Yield % for the quarter that ended in Feb. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+0 %
=0 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of 0.00% mean?
Newbury Pharmaceuticals AB (OSTO:NEWBRY) has a Shareholder Yield % of 0.00% as of Feb. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Newbury Pharmaceuticals AB and its competitors. According to the industry distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 966 companies in the Drug Manufacturers industry.
Is Newbury Pharmaceuticals AB's Shareholder Yield % too high?
Newbury Pharmaceuticals AB's current Shareholder Yield % is 0.00%. Based on the distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 966 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 966 companies for Shareholder Yield %. This places Newbury Pharmaceuticals AB in the lower half of its industry. The industry median Shareholder Yield % is 0.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.35, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Newbury Pharmaceuticals AB and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current Shareholder Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB (OSTO:NEWBRY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr3.20, compared to a current price of kr2.48 — trading 22.5% below its estimated fair value. The current Shareholder Yield % is 0.00%. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (OSTO:NEWBRY), the current Shareholder Yield % is 0.00% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newbury Pharmaceuticals AB (OSTO:NEWBRY) Overvalued in 2026?

Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued. The current stock price of kr2.48 is trading 22.5% below its estimated GF Value™ of kr3.20. GuruFocus considers Newbury Pharmaceuticals AB to be Modestly Undervalued.

Key valuation signals for OSTO:NEWBRY:

  • Shareholder Yield %: 0.00%
  • GF Value™: kr3.20 vs. price of kr2.48 (22.5% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the OSTO:NEWBRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Newbury Pharmaceuticals AB Business Description

Other Exchanges P52:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score

Get the complete analysis for OSTO:NEWBRY

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.48
Price
kr3.20
GF Value